Hernandez I, et al. - This study undertaken to present variations in list prices, net prices, and discounts for branded pharmaceutical products for which US sales are reported by publicly traded companies, and to determine the extent to which list price increases were offset by increases in discounts. Researchers carried out a retrospective descriptive study utilizing 2007-2018 pricing data from the investment firm SSR Health for branded products available before January 2007 with US sales reported by publicly traded companies (n = 602 drugs). Researchers calculated net prices by compiling company-reported sales for each product and the number of units sold in the US. Despite the fact that discounts somewhat offset the list price rises of branded products from 2007 to 2018, there was still a substantial increase in net prices over this period.